Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pritumumab ADC
- Development stage
- Preclinical
- Lead developer
- Nascent Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pritumumab ADC is an antibody-drug conjugate (ADC) being developed by Manhattan BioSolutions in collaboration with Nascent Biotech. The candidate consists of pritumumab, a natural human monoclonal antibody that targets the extracellular form of vimentin, conjugated to a cytotoxic payload. Vimentin is an intermediate filament protein that is overexpressed on the surface of various cancer cells, particularly in brain and pancreatic cancers, and is associated with tumor growth and metastasis. The ADC utilizes Manhattan BioSolutions' proprietary platform, which typically employs a legumain-activated linker and a topoisomerase I inhibitor (TOP1i) payload, such as exatecan derivatives. Pritumumab has demonstrated the ability to cross the blood-brain barrier, potentially allowing the ADC to treat primary brain tumors and brain metastases. The program is currently in the preclinical stage, with studies focused on vimentin-positive advanced or metastatic solid tumors.
- Other names
- Pritumumab conjugate
02
Targets
VIM (Vimentin)
Beyond the preview
Go deeper on pritumumab ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pritumumab ADC.